PVR and prostate carcinoma: Also, when analyzing the MFI, we found a higher expression of CD155 compared to the other ligands in the DU145 cells; additionally, we observed that the expression of CD155 was very abundant in DU145 in comparison with the 22Rv1 and LNCaP prostate cancer cells (Figure 2(d), ∗∗∗p < 0.001).